Block & Leviton is investigating Stryker Corporation for potentially violating securities laws by allegedly misrepresenting the status of a manufacturing problem affecting its peripheral vascular business. While Stryker's CEO initially claimed the issue was resolved in Q3 2026, the CFO later revealed at a healthcare conference that the problem persisted into Q4, causing the stock to drop about 8%. The investigation aims to determine if Stryker misled investors about the health of its business. Investors who suffered losses may be eligible to recover damages through legal action initiated by Block & Leviton.
Stryker Corporation's stock is currently priced at USD 277.92 on Pluang, showing a modest decline of 0.79% as of Sep 18, 2026 22:01 WIB. The stock's market cap stands at $107.45 billion, with a dividend yield of 1.26%, reflecting steady investor interest despite recent concerns.
